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Fanconi anemia (FA) is a genetic disease that is characterized by several congenital abnormalities and pro-
gressive bone marrow failure and is associated with an increased susceptibility to malignant disorders.
Currently, the only potential cure for hematological disorders is hematopoietic stem cell transplantation
(HSCT). However, 1 of the most common complications after HSCT is the development of oral chronic graft-
versus-host disease (cGVHD), which is also a risk factor for the development of cancer, particularly oral
squamous cell carcinoma. Therefore, the purpose of this study was to describe the prevalence and charac-
teristics of oral manifestations compatible with cGVHD in patients diagnosed with FA according to the
National Institutes of Health (NIH) consensus criteria. A total of 96 patients (51 females, 45 males; median
age, 16 years) with FA, who were in medical follow-up after HSCT at the outpatient clinic of the bone marrow
transplantation unit (Hospital de Clínicas from the Universidade Federal do Paraná) underwent an oral
evaluation between January 2013 and December 2013. Post-HSCT periods varied from 1 to 261 months and
were divided into 3 periods: immediate post-HSCT period; intermediate post-HSC period, and late post-HSCT
period. Among the evaluated patients, 40 of 96 (42%) presented with oral manifestations of cGVHD, with 29 of
40 (73%) of these patients in the late post-HSCT period. NIH scale scores varied from 0 to 10, and lichenoid
and hyperkeratotic lesions were the abnormalities most frequently observed (100%). Overall, a high preva-
lence of oral manifestations was observed for cGVHD patients with FA. These data highlight the importance of
monitoring oral manifestations compatible with cGVHD to identify and treat individuals with a higher risk of
developing oral cancer.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Fanconi anemia (FA) is a rare genetic disease that is
related to chromosomal instability and the defective repair of
DNA damage [1,2]. FA is also characterized by congenital
malformations, progressive bone marrow failure, and a 700-
fold increase in the risk for head and neck squamous cell
carcinoma (SCC) [1-3].
Currently, hematopoietic stem cell transplantation
(HSCT) is the only potential cure for hematologic disorders
related to FA [3,4]. However, after this procedure, patients
have an additional 4-fold higher risk for head and neck SCC
[5]. Moreover, patients subjected to HSCT are susceptible todgments on page 279.
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ty for Blood and Marrow Transplantation.chronic graft-versus-host disease (cGVHD), which is a com-
mon alloimmune and autoimmune complication [6]. In-
dividuals with cGVHD can present with hyperkeratotic and
lichenoid lesions in the mouth, erythema, ulcers, atrophy,
and pain [7]. Patients with cGVHD also have an increased risk
of developing malignancies [8-10].
Therefore, the purpose of this study was to evaluate the
prevalence of oral manifestations of cGVHD in FA patients
who underwent allogeneic HSCT, according to the National
Institutes of Health (NIH) consensus criteria [7], and to
describe the characteristics and distribution of these mani-
festations in the mouth.
MATERIALS AND METHODS
This cross-sectional study was performed between January 2013 and
December 2013. Patients, regardless of age, with a conﬁrmed FA diagnosis
(positive diepoxy-butane test), who were subjected to allogeneic HSCT and
underwent follow-up at the outpatient clinic of the bone marrow trans-
plantation unit of the Hospital de Clínicas (Universidade Federal do Paraná)
were evaluated. Patients’ gender and age, time since HSCT, donor’s
Table 1
Demographic Data and Information Related to HSCT and Post-HSCT Periods for Patients with FA
Characteristic Patients with Oral
Manifestations of cGVHD
Patients without Oral
Manifestations of cGVHD
Total
No. of patients 40 (42%) 56 (58%) 96 (100%)
Age, median (range), yr* 18 (5-32) 13 (6-42) 16 (5-42)
Gender
Male 22 (55%) 23 (41%) 45 (47%)
Female 18 (45%) 33 (59%) 51 (53%)
Conditioning regimen
Cyclophosphamide 20 (50%) 24 (43%) 44 (46%)
Combination chemotherapy 14 (35%) 28 (50%) 42 (44%)
Chemotherapy þ total body irradiation 6 (15%) 4 (7%) 10 (10%)
Stem cell source and donor
Related bone marrow 19 (48%) 24 (43%) 43 (45%)
Unrelated bone marrow 11 (28%) 16 (29%) 27 (28%)
Related cord blood 0 (0%) 1 (2%) 1 (1%)
Unrelated cord blood 3 (7%) 7 (12%) 10 (10%)
Unrelated peripheral blood 1 (2%) 0 (0%) 1 (1%)
Haploidentical 6 (15%) 8 (14%) 14 (15%)
Donor age, median (range), yr 19 (0-60) 13.5 (0-64) 17 (0-64)
Donor gender  patient gender
Male  male 10 (25%) 17 (30%) 27 (28%)
Male  female 11 (28%) 12 (21%) 23 (24%)
Female  female 12 (30%) 16 (29%) 28 (29%)
Female  male 7 (17%) 11 (20%) 18 (19%)
Time after HSCT, median (range), mo 103 (3-211) 41.5 (1-261) 62.5 (1-261)
Post-HSCT period*
Immediate (within 12 mo after HSCT) 3 (7%) 16 (29%) 19 (20%)
Intermediate (13-47 mo after HSCT) 8 (20%) 14 (25%) 22 (23%)
Late (>48 mo after HSCT) 29 (73%) 26 (46%) 55 (57%)
History of aGVHDy 10 (25%) 10 (18%) 20 (21%)
History of cGVHD*,y,z 27 (68%) 15 (27%) 42 (44%)
aGVHD indicates acute graft-versus-host disease.
* P < .05.
y Data collected from medical records.
z cGVHD in different organs, besides the mouth.
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tions were collected from each patient’s medical records. Oral examinations
were performed in the dental unit under reﬂective light by a dentist with
experience applying theNIHscale (intrarater intraclass correlation coefﬁcient,
.969; inter-rater intraclass correlationcoefﬁcient, .934).Oralmucosawasdried
with gauze and then observed for any alterations. Oral manifestations of
cGVHDwere scoredbasedondiagnosticsanddistinctive signs according to the
oral cGVHD activity assessment criteria publishedby theNIH [7]. The type and
distribution of the lesions compatible with cGVHD were also assessed and
registered in a clinical record speciﬁcally developed for this study.
Patients were excluded if they had undergone more than 1 HSCT, if the
oral examination was prevented because of discomfort caused by oral can-
cer, or if their medical data were incomplete.
There is no standard criteria used to distinguish patients according to the
time after transplantation. Based on the outpatient care standards adopted at
this center and on the major complications observed after transplantation,
periods in the present studywere separated into 3 categories: (1) immediate
post-HSCT period (up to 12months after transplantation), the stage inwhich
many individuals are stabilizing their immunity and blood cell count and are
under immunosuppressive therapy; (2) intermediate post-HSCT period (13
to 47 months after transplantation), the stage in which most of the compli-
cations were either detected or resolved, as cGVHD often occurs in the ﬁrst 3
years after the transplantation; and (3) late post-HSCT (>47 months after
transplantation) period, in which patients commonly do not use any medi-
cation, andwhen they are usually released to their home town and came less
frequently to the clinical evaluations.
Descriptive and analytic statistical analyses were performed. The chi-
squared test, Fisher’s exact test, and the linear trend chi-squared test were
used to evaluate the association between the presence of oral manifesta-
tions of cGVHD, demographic data, and variables related to HSCT. It was
considered a statistical signiﬁcant association whenever P  .05. This study
was approved by the ethics committee in research of the Universidade
Federal do Paraná and each patient, or his/her guardian, signed an informed
consent form.
RESULTS
A total of 103 individuals with FA who underwent alloge-
neicHSCTwereevaluated.Sevenpatientswereexcludedbasedon the criteria described in the Materials and Methods,
including 2 individuals with oral cancer. The ﬁnal cohort
included 96 patients (51 [53%] females and 45 [47%] males)
with a median age of 16 years. Demographic data, HSCT char-
acteristics, and GVHD data for this cohort are listed in Table 1.
Approximately 25% of the patients evaluated were
receiving immunomodulatory prophylaxis or treatment for
GVHD. In most cases, systemic medication was administered
exclusively, and this included cyclosporine, mycophenolate
mofetil, sirolimus, and prednisone alone or in combination.
Five (5%) patients were applying a topical corticosteroid rinse
to their oral mucosa. However, only 1 of these patients was
using the topical medication exclusively.
Based on the NIH consensus criteria, 40 patients (42%)
presented with oral manifestations compatible with cGVHD.
Moreover, most of them presented these manifestations
during the late post-HSCT period (n ¼ 29; 73%).
According to the medical record data collected, 25% of the
individuals with oral manifestations of cGVHD had previ-
ously presented with acute GVHD, and 68% had a history of
cGVHD that affected several organs besides the mouth. In
addition, patient age, post-HSCT period, and history of
manifestations of cGVHD in other organs were found to have
statistically signiﬁcant associations with the presence of oral
alterations compatible with cGVHD, according to the NIH
consensus (P < .001, P ¼ .007, and P ¼ .010, respectively).
All patients with oral manifestations of cGVHD were
classiﬁed according to the diagnostic signs exhibited,
including hyperkeratotic plaques and lichenoid lesions.
White plaques were observed in 95% (n ¼ 38) of the patients
with oral lesions of cGVHD. Lichenoid manifestations, atro-
phy, erythema, and ulcers were also identiﬁed. However, the
Figure 1. Prevalence and type of oral manifestations of cGVHD in patients with FA, according to time post-HSCT.
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patients with oral alterations of cGVHD according to their
post-HSCT period is presented in Figure 1.
The tongue, buccal mucosa, and hard palate were the
locations most involved by manifestations of cGVHD. Sites of
the oral mucosa that were affected are listed in Table 2.
NIH scoring for the present cohort ranged from 0 to 10,
and the average score was .82 (1.642). When only patients
with oral lesions of cGVHDwere considered, the average NIH
score was 1.95 (2.074). When oral manifestations of cGVHD
according to time post-HSCT period were considered, the
most severe cases (indicated with a score of 10) occurred
during the intermediate post-HSCT period (Figure 2).
Of the patients who presented oral manifestations
compatible with cGVHD, 30 of 40 (75%) maintained persis-
tent lesions after treatment, and 10 of 40 patients (25%) had
evidence of disease activity (ie, diagnostic signs or proven
distinctive signs associated with a need for treatment). The
characteristics of the patients with oral manifestations of
cGVHD that needed treatment are summarized in Table 3.
DISCUSSION
To our knowledge, this is the ﬁrst study to evaluate oral
manifestations of cGVHD in a group of patients with FA.
Moreover, in contrast with other papers describing oralTable 2
Distribution of cGVHD Lesions according to Different Sites of the Oral Mucosa
Location Hyperkeratotic Plaques Lichenoid Le
Lip 3 2
Labial mucosa 1 2
Unilateral buccal mucosa 4 0
Bilateral buccal mucosa 3 5
Unilateral retrocomissura 4 0
Bilateral retrocomissura 10 2
Tongue dorsum 14 1
Ventral tongue 0 2
Unilateral tongue border 3 3
Bilateral tongue border 1 3
Hard palate 20 0
Gingiva 6 1
Total 69 21
Mucoceles are not described in this table because none of these lesions were idencGVHD, most of the individuals of this cohort were young,
consistent with the observation that FA presents a low life
expectancy and is commonly diagnosed during childhood.
In the present cohort, 42% of the patients developed oral
manifestations compatible with cGVHD, according to the NIH
consensus criteria. However, most of the individuals had
favorable HSCT characteristics, such as a young age and
grafted bone marrow cells obtained from a sibling, and their
conditioning regimen included low doses of cyclophospha-
mide [11,12]. It is hypothesized that patients with FA have an
increased susceptibility to cGVHD because of hypersensitiv-
ity towards substances present in the conditioning regimen.
This could cause greater tissue damage and facilitate the
recognition of patients’ antigens by donor cells.
In a study of childrenwho underwent HSCT, Treister et al.
[13] identiﬁed a similar prevalence (36%) of oral GVHD. Fassil
et al. [14] also observed oral manifestations in approximately
23% of the cGVHD patients they examined. This difference
may be due to the conservative criteria utilized in the latter
study, where the presence of oral lesions was only consid-
ered when the NIH scale scores were 3. Overall, the prev-
alence and incidence of alterations due to cGVHD are
reported to vary from 23% to 95%, respectively [14-21].
In the present study, the distribution of oral lesions of
cGVHD was found to vary widely, yet a greater involvementsions Erythema Atrophy Ulcers Total
2 0 3 10
2 0 0 5
0 0 1 5
5 0 1 14
0 0 1 5
0 0 0 12
1 9 0 25
1 0 1 4
1 1 1 9
0 0 0 4
1 0 1 22
0 0 0 7
13 10 9 122
tiﬁed in the present cohort.
Figure 2. NIH scoring of oral manifestations of cGVHD according to the time of presentation post-HSCT.
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consistent with data reported in the literature [15,22].
However, a large number of hyperkeratotic plaqueswere also
observed on the hard palate in this study, thereby indicating
that this location should also be examined with attention
during clinical examinations, particularly in patients with FA.
Lichenoid lesions were observed more frequently during
the immediate post-HSCT period, ulcers were seen only
during the intermediate post-HSCT stage, and the number of
patients with hyperkeratotic plaques increases with time
after transplantation, being observed more frequently in the
late post-HSCT period (Figure 1). Although this is a cross-
sectional study, the results suggest the presence ofTable 3
Demographic Data and HSCT and Post-HSCT Characteristics of Patients with Oral M
Characteristic Patients with Oral Manifesta
of cGVHD, under Treatment
No. of patients 10 (25%)
Age, median (range), yr 14 (5-22)
Gender
Male 4 (40%)
Female 6 (60%)
Conditioning regimen
Cyclophosphamide 1 (10%)
Combination chemotherapy 5 (50%)
Chemotherapy þ total body irradiation 4 (40%)
Stem cell source and donor
Related bone marrow 1 (10%)
Unrelated bone marrow 5 (50%)
Unrelated cord blood 0 (0%)
Unrelated peripheral blood 1 (10%)
Haploidentical 3 (30%)
Donor age, median (range), yr 31.5 (16-37)
Donor gender  patient gender
Male  male 1 (10%)
Male  female 5 (50%)
Female  female 3 (30%)
Female  male 1 (10%)
Time after HSCT, median (range), mo 24.5 (3-108)
Post-HSCT periods
Immediate (within 12 mo after HSCT) 3 (30%)
Intermediate (13-47 mo after HSCT) 5 (50%)
Late (>48 mo after HSCT) 2 (20%)
History of aGVHD* 7 (70%)
History of cGVHD*,y 9 (90%)
* Data collected from medical records.
y cGVHD in different organs, besides the mouth.time-related changes in oral manifestations of cGVHD. Lon-
gitudinal studies are needed to evaluate the incidence and
patterns of oral cGVHD over time.
Salivary glands appear to be susceptible to cGVHD
because of their high expression of histocompatibility anti-
gens and their exposure to pathogenic lymphocytes [23]. An
analysis of salivary ﬂowwas not performed in this study, and
none of the patients complained of xerostomia. Moreover,
most of the cohort did not receive total body irradiation,
which is a contributing factor to decreased salivary ﬂow rates
and symptoms of dry mouth in patients undergoing HSCT.
There were also no cases of rampant caries that could be
associated with the reduced saliva that was observed [24,25].anifestations Compatible with cGVHD, according to Treatment
tions
(active)
Patients with Oral Manifestations
of cGVHD, without Treatment
Total
30 (75%) 40 (42%)
19 (8-32) 18 (5-32)
18 (60%) 22 (55%)
12 (40%) 18 (45%)
19 (63%) 20 (50%)
9 (30%) 14 (35%)
2 (7%) 6 (15%)
18 (60%) 19 (48%)
6 (20%) 11 (28%)
3 (10%) 3 (7%)
0 (0%) 1 (2%)
3 (10%) 6 (15%)
15.5 (0-60) 19 (0-60)
9 (30%) 10 (25%)
6 (20%) 11 (28%)
9 (30%) 12 (30%)
6 (20%) 7 (17%)
115 (28-211) 103 (3-211)
0 (0%) 3 (7%)
3 (10%) 8 (20%)
27 (90%) 29 (73%)
3 (10%) 10 (25%)
18 (60%) 27 (68%)
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and they usually have less hyposalivation and a lower rate of
xerostomia [13]. Mucocele was not observed in the present
cohort, as well, which can be explained by the fact that they
may be temporary and have often spontaneous remission.
Limited mouth opening due to sclerosis is 1 of the diag-
nostic signs for oral cGVHD. However, some authors suggest
that restricted mouth opening is sometimes related to pain,
and therefore, is not truly associatedwith sclerosis.Moreover,
a common characteristic of patientswith FA is the presence of
microstomia [26], which may be another confounding factor
in identifying limited mouth opening and could limit the use
of the NIH scale as an index for cGVHD in patients with FA.
Thus, microstomia was not evaluated in this study.
Although more than 90% of the patients in the present
cohort received a low overall NIH scale score, some in-
dividuals did receive high values. In particular, the latter had
ulcerated lesions, which can limit oral ingestion, compro-
mise an individual’s speaking, and negatively affect quality of
life. In severe cases, systemic therapy and pain control with
analgesics and anesthetic drugs may be required [7,27]. In
the current study, a pain questionnaire or scale was not
applied, as pain was an infrequent complaint in the clinic,
which is a distinct difference from other studies [19,22,28].
Moreover, none of the patients in the current study who
developed ulcers reported symptoms in their mouth or had
received analgesic therapy at the time of consultation.
Many of the individuals who did not develop cGVHD
treatment presented with white lesions more than 4 years
after HSCT (n ¼ 27; 90%). This observation supports the hy-
pothesis that these lesions are not active manifestations of
the disease, as cGVHD usually occurs up to the third year
after HSCT [7]. It is also possible for individuals to present
with conditions compatible with cGVHD after completing
therapy. Therefore, we suggest that cGVHD classiﬁcation
should be realized not only according to temporal criteria or
clinical changes, but also according to disease activity. Active
oral manifestations of cGVHD are deﬁned in the presence of
diagnostic signs or certiﬁed distinctive signs of the disease
with indication for therapy [14].
As expected, most of the individuals with active oral
manifestations of cGVHD (in need of treatment) had under-
gone transplantation with features more prone to the risk of
developing cGVHD, such as older and unrelated donors and
more aggressive conditioning regimens, when compared
with patients diagnosed with cGVHD according to the NIH
consensus criteria. Moreover, although the majority of in-
dividuals (48%) diagnosed with oral cGVHD based on the NIH
classiﬁcation received stem cells from sibling, in the group of
patients with active oral lesions, only 10% of the patients had
sibling donors. Furthermore, in the active cGVHD group (10
patients under treatment) most of the individuals were in
the intermediate post-HSCT period, different from those 40
patients diagnosed with cGVHD according to the NIH
consensus criteria, who had undergone HSCT for 48 months
or more (Tables 1 and 3).
In the present study, 75% of the patients who manifested
oral changes compatible with cGVHD presented white le-
sions that persisted during treatment. According to the NIH
consensus criteria, these oral manifestations could be
considered representative of cGVHD [7], although thera-
peutically, they are not considered active. Currently, it is not
possible to determine whether these lesions represent
cGVHD manifestations versus newly isolated hyperkeratotic
plaques. An oral biopsy would provide a more deﬁnitivediagnosis, although an oral cGVHD diagnosis is commonly
established based on clinical manifestations. In the present
cohort, all of the individuals who were diagnosed with oral
manifestations of cGVHD presented sufﬁcient clinical signs
to detect cGVHD, according to the NIH consensus criteria [7].
The decision to undergo an oral biopsywas dependent on the
clinical macroscopic changes. Oral erytroplakias, atrophy, or
leukoplakias, which get larger andworse as time goes by, and
those with a verrucous surface should be biopsied. However,
stable and homogeneous hyperkeratotic plaques can be fol-
lowed up. Nevertheless, evaluations should be more
frequently in high-risk patients.
The NIH scale for oral manifestations of cGVHD has been
validated, and despite its limitations, it is considered a tool
that is easily applied. It also has a good overall reliability
score, especially if the individuals performing the NIH
scoring have experience with the scale and its application
[29,30]. However, as a diagnostic tool, it remains to be
determined whether this scale overestimates the number of
patients exhibiting manifestations of cGVHD in the late post-
HSCT period. Therefore, further studies should include
microscopic evaluations of late lesions to determine if the
lesions are manifestations of cGVHD versus hyperkeratotic
changes with some degree of dysplasia and autonomous
progression that are unrelated to cGVHD.
Approximately 30% of the individuals evaluated were
classiﬁed as high-risk for the development of oral cancer
using an algorithm that considered age, time since trans-
plantation, and presence of oral lesions compatible with
cGVHD. Inparticular, patientswith FAwho undergoHSCTand
manifest cGVHD represent a high-risk group for the devel-
opment of oral SCC, even at a young age and in the absence of
other classical risk factors, such as smoking and alcohol
consumption. For this reason, these individuals, especially
those who are older and those in late post-HSCT period,
should be evaluated more frequently by an oral medicine
specialist as part of a screening program for oral cancer.
It is important for professionals on a transplantation team
to be able to recognize the clinical characteristics of oral le-
sions in patients undergoing allogeneic HSCT, as this may
facilitate an early diagnosis of cGVHD and the prevention of
more severe stages of the disease. Furthermore, knowledge
of the prevalence of these manifestations in individuals with
FA is relevant to the evaluation of patients with increased
risk for the development of potentially malignant disorders
or malignancies in the oral cavity.ACKNOWLEDGMENTS
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